Searched for
ZAYNICH EUROPE MARKET
Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
Market Wrap: D-Street logs 7th straight loss on auto, IT sell-off; Sensex falls 61 points, Nifty below 24,700Indian markets recorded their seventh consecutive loss, with Nifty and Sensex closing marginally down amidst mixed global cues. The rupee s...
Wockhardt activates Zaynich push, eyes global licensing dealsWockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions ...
Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, EuropeWockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europ...
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Co...
Wockhardt raises Rs 480 crore to pare debt, fund drug trialWockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of gl...